Treating Tough Tumors by Exploiting Their Iron ‘Addiction’

Researchers at UC San Francisco have successfully leveraged an FDA-approved drug to halt growth of tumors driven by mutations in the RAS gene, which are famously difficult to treat and account for about one in four cancer deaths. Taking advantage of what they discovered to be the cancer cells’

Solving the Mystery of a Stubborn – and Common – Cancer Gene

One of the major successes of decades of cancer research has been the development of drugs that specifically inactivate oncogenes, genes that function abnormally, causing cells to behave erratically, become malignant and make tumors. These drugs are highly effective treatments for cancers caused by

UCSF Is Top Public Recipient of NIH Funding for 15th Year

For the 15th year in a row, UC San Francisco garnered the top spot among public institutions in funding from the National Institutes of Health (NIH) in 2021. UCSF continued to rank highly among all public and private institutions nationwide, ranking fourth overall. The University was awarded nearly

Immune Cells Leave Fingerprints on Tumors Metastasized to the Brain Offering Clues to Future Therapies

Using data from over 100,000 malignant and non-malignant cells from 15 human brain metastases, UCSF researchers have revealed two functional archetypes of metastatic cells across 7 different types of brain tumors, each containing both immune and non-immune cell types. Their findings, published the

3 Researchers Named 2021 Fellows of American Association for the Advancement of Science

Three UC San Francisco researchers have been selected as 2021 fellows of the American Association for the Advancement of Science (AAAS), the world's largest multidisciplinary scientific society and a leading publisher of cutting-edge research through its Science family of journals. They are among

UCSF Researchers Receive 2021 ASPIRE Awards for High-Risk, High-Reward Projects

Three scientific research projects led by UCSF investigators have been selected to receive 2021 ASPIRE Awards by the Mark Foundation for Cancer Research. The Mark Foundation's ASPIRE (Accelerating Scientific Platforms and Innovative Research) program enables innovative approaches to solving

Addressing High Lung Cancer Rates Among Female Asian Non-Smokers

While smoking is the top risk factor for lung cancer, Asian women in the United States who have never smoked are currently twice as likely to develop the disease than female non-smokers of other ethnicities. The FANS (Female Asian Never Smokers) Study aims to collect data from Asian American women